Bio-Techne names Steve Crouse president of diagnostics segment

Bio-Techne Corporation (NASDAQ: TECH) announced leadership changes within its diagnostics and spatial biology segment. Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment on March 1, 2026, and will remain with the company for a period to support the transition.

Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed to succeed McManus as President of the Diagnostics and Spatial Biology Segment, effective March 1, 2026.

Crouse brings over two decades of experience as a senior life sciences leader. In his current role, he oversees Bio-Techne's portfolio of protein analysis instruments and immunoassays. During his four-year tenure, he has led strategic initiatives and launched several platforms. Before joining Bio-Techne, Crouse served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He holds an MBA from the Marshall School of Business at the University of Southern California and a master's degree in biochemistry from Georgetown University.

"Matt has played a key role in optimizing our organization, including driving the strategic divestiture of the Exosome business," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "I'm delighted that Steve will be stepping up to take on the role of President, with his strong track record, visionary leadership, and over 20 years' experience in advancing innovative life science solutions making him an ideal fit for this role."

Bio-Techne is a global life sciences company that provides tools and bioactive reagents for research and clinical diagnostic communities. The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.

You May Also Be Interested In

• Uber Is Said To Be In Advanced Talks On Delivery Hero Takeover - Bloomberg
• Weave adds AI receptionist and insurance tools for healthcare
• Xcel Brands signs licensing deal for Christie Brinkley home decor line